Pakistan's MedIQ raises $6mn to expand digital healthcare platform across GCC
The round also involved follow-on investment from existing backers, the venture said.
The healthtech venture, which expanded to Saudi Arabia in 2023, said the fresh capital will be used to fuel its further expansion in the region. The venture plans expansion to Qatar and neighbouring GCC countries.
Founded by physician-turned-health economist and entrepreneur Dr. Saira Siddique, MedIQ said it aims to become the 'operating system' for healthcare in the MENA region, delivering greater cost efficiency, accountability, and convenience through technology.
'People don't just suffer from illnesses — they suffer from the system,' said Dr. Siddique.
'MedIQ isn't just another health app. We're building the backbone of digital healthcare – a scalable infrastructure that improves outcomes and reduces costs,' she said.
MedIQ's growth plans include broadening its technological reach and the expansion of a unique, proprietary B2B and B2B2C digitally integrated hybrid healthcare ecosystem, which will support the rapid modernisation of the sector.
This includes AI-driven digitisation of healthcare facilities and back-office operations of insurance companies to provide a digitally supported, seamless, patient-centred experience for improved patient satisfaction.
MedIQ was born out of the personal health crisis experienced by Dr. Saira Siddique, who was left paralysed and hospitalised for over a year.
During this time, she experienced firsthand the fragmented and inaccessible nature of Pakistan's healthcare system.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TECHx
3 days ago
- TECHx
Ovasave Raises $1.2M to Expand Fertility Platform in MENA
Home » Startups » Ovasave Raises $1.2M to Expand Fertility Platform in MENA Ovasave, a Hub71-based FemTech startup focused on fertility and hormonal health, has announced the successful completion of its pre-seed funding round. The company raised $1.2 million from a mix of regional and international investors. The round was led by PlusVC, Annex Investments, and New York-based 25 Madison. Additional funding came from strategic angel investors and family offices in the UAE and Saudi Arabia. The funding reflects growing investor confidence and demand for innovation in women's health across the region. Founded in 2023, Ovasave offers a digital-first platform for women, covering fertility testing, egg freezing, hormone management, and menopause care. The platform integrates at-home hormone testing, virtual consultations, personalized supplement protocols, and access to top fertility clinics. The startup has also introduced corporate fertility benefits programs to help organizations support employee reproductive health. According to Ovasave, the $1.2 million capital will be used to: Expand across the GCC region Scale corporate partnerships Launch the next version of its mobile app The upcoming app update will feature menstrual cycle tracking, symptom monitoring, AI-driven treatment protocols, and access to care. Ovasave will also expand its services to include support for perimenopause and menopause, addressing a previously overlooked stage of women's health. The funding announcement aligns with ongoing healthcare reforms and national support for women's health in the UAE. Ovasave is registered with the Department of Health – Abu Dhabi and is backed by Abu Dhabi's tech ecosystem, Hub71. Majd Abu Zant, Co-founder of Ovasave, noted that Abu Dhabi's focus on healthcare, innovation, and entrepreneurship provides the right environment for high-impact ventures. He confirmed Ovasave's expansion into Saudi Arabia and the wider MENA region. FemTech Analytics reported that the MENA FemTech market is projected to reach $3.8 billion by 2031, growing at a CAGR of 15%. Ovasave Co-founder and CEO Torkia Mahloul emphasized the need for timely fertility and hormonal care. She said the funding will help scale a platform offering personalized and accessible care for women across different life stages. The startup is also committed to public education, with campaigns like 'Fertility Your Way,' in partnership with Merck Gulf, offering free AMH screenings to over 500 women in the UAE. Ovasave has partnered with employers such as Aldar, Boston Consulting Group, and WeWork to raise awareness around fertility in the workplace. The company reported that investor confidence and regional demand signal a shift in how fertility and hormonal health are perceived. Ovasave aims to lead innovation in women's health across the Middle East.
Zawya
3 days ago
- Zawya
KFSHRC performs world's first robotic-assisted BiVAD Implantation
A minimally invasive robotic surgery offers a life-saving option for high-risk patients who cannot undergo transplants or traditional open-heart procedures King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh has successfully performed the world's first implantation of two artificial pumps for biventricular support (BiVAD-HMIII) using robotic technology on a patient with advanced heart failure. This groundbreaking procedure opens new horizons in circulatory support techniques for patients with complex cardiac conditions and marks a medical achievement that culminated in the patient's recovery within a short period following the surgery. The procedure represents a major advancement in the treatment of bilateral heart failure, which was traditionally performed through full sternotomy, an approach associated with higher surgical risks and prolonged recovery. However, the cardiac surgery team at KFSHRC, led by Prof. Feras Khaliel, successfully performed the operation through small incisions using remotely controlled high-precision robotic arms, resulting in reduced blood loss, lower risk of infection, and faster patient recovery. The 61-year-old patient was admitted after spending over two months bedridden, suffering from end-stage heart failure unresponsive to medical therapy, in addition to multiple chronic conditions including diabetes, stroke, and renal impairment. After a comprehensive clinical evaluation, the patient was deemed ineligible for a heart transplant, making robotic implantation of the artificial pumps a vital and unique solution suited to his health status. This milestone reflects the integration of expertise across multiple departments at KFSHRC including cardiac surgery, cardiology, anesthesia, critical care, biomedical engineering, and advanced life support. The procedure was meticulously planned and benefited from 3D imaging technologies, real-time surgical navigation, and innovative solutions for safely securing the mechanical assist devices. KFSHRC aims to publish the results of this procedure in peer-reviewed medical journals and present them at global cardiology conferences to promote knowledge exchange and establish innovative partnerships with leading international centers in robotic care and advanced heart failure management. This achievement adds to KFSHRC's track record in robotic surgery which includes the world's first fully robotic heart transplant and the World's First Robotic-Assisted Artificial Heart Pump Implantation. These milestones serve as evidence of its leadership in adopting cutting-edge cardiac technologies and managing critical conditions with the highest standards of precision and safety, further reinforcing its position as a leading academic medical center both regionally and globally. It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 20th globally in the list of the world's top 250 Academic Medical Centers for the second consecutive year and has been recognized as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2024 Brand Finance rankings. Additionally, in the same year, it was ranked among the world's best 250 hospitals and included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine.
Al Etihad
5 days ago
- Al Etihad
Mubadala announces additional investment in PCI Pharma Services
15 July 2025 17:28 A. SREENIVASA REDDY (ABU DHABI)Mubadala, the Abu Dhabi-based sovereign investor, has announced additional investment in PCI Pharma Services, a global leader in contract development and manufacturing (CDMO) for complex biologics and innovative investment is being made alongside private equity firms Bain Capital, Kohlberg, and existing investor Partners strategic transaction will see PCI enter its next phase of growth with support from this strong consortium of global investors. While financial terms were not disclosed, the partnership is expected to accelerate PCI's global expansion and bolster its capabilities in biopharma a post on X, Mubadala stated: 'This marks our continued support of PCI, following our initial commitment in 2020. Over the past five years, the company has demonstrated the strength of its global capabilities and its role in advancing innovation to improve patient access and outcomes.'Mina Hamoodi, Head of Healthcare at Mubadala, commented: 'Our reinvestment in PCI reflects our deep conviction in the company's mission, leadership, and long-term potential. At this important juncture, we are delighted to welcome Bain Capital, an industry-leading healthcare investor with deep expertise in growing pharma services businesses, as a partner.'She added: 'We look forward to partnering with Bain and Kohlberg, and working closely with PCI's outstanding management team, as the company enters its next chapter of accelerated growth.'Partners Group will also continue to support PCI with a minority investment. Sujit John, Managing Director, Private Equity Health & Life at Partners Group, said: "PCI's market position, reputation, and world-class capabilities strategically position the Company to be the partner of choice for customers. We look forward to supporting PCI and the new ownership group in driving the Company into its next phase of growth.'Headquartered in Philadelphia, PCI has over 7,500 employees across 38 sites in seven countries. The company offers integrated services across the entire drug development lifecycle, and its continued investments in sterile injectables and high-potency manufacturing will strengthen pharmaceutical supply chains in the US and beyond. Source: Aletihad - Abu Dhabi
